Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults.

ABSTRACT:

Importance

The live attenuated herpes zoster vaccine (ZVL) is recommended for immunocompetent adults 60 years or older, but the efficacy wanes with age and over time. A new adjuvanted herpes zoster subunit vaccine (HZ/su) has higher efficacy but might be more expensive. The choice of vaccines depends on their relative values.

Objective

To assess the cost-effectiveness of HZ/su.

Design, setting, and participants

Markov decision model with transition probabilities based on the US medical literature. Participants were immunocompetent adults 60 years or older. Data were derived from participant groups ranging in number from less than 100 to more than 30 000 depending on the variable assessed. The study dates were July 1 to 31, 2017.

Exposures

No vaccination, ZVL (s

SUBMITTER: Le P 

PROVIDER: S-EPMC5838796 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature